GB0723882D0 - Methods for the detection of a threatened miscarriage - Google Patents

Methods for the detection of a threatened miscarriage

Info

Publication number
GB0723882D0
GB0723882D0 GBGB0723882.7A GB0723882A GB0723882D0 GB 0723882 D0 GB0723882 D0 GB 0723882D0 GB 0723882 A GB0723882 A GB 0723882A GB 0723882 D0 GB0723882 D0 GB 0723882D0
Authority
GB
United Kingdom
Prior art keywords
detection
methods
threatened miscarriage
miscarriage
threatened
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0723882.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leicester
Original Assignee
University of Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leicester filed Critical University of Leicester
Priority to GBGB0723882.7A priority Critical patent/GB0723882D0/en
Publication of GB0723882D0 publication Critical patent/GB0723882D0/en
Priority to PCT/GB2008/051162 priority patent/WO2009071950A1/en
Ceased legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948Sedatives, e.g. cannabinoids, barbiturates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/368Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Anesthesiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a method for detecting the outcome of pregnancy in pregnant mammals, particularly humans, presenting with a threatened miscarriage. In particular, the invention relates to a method for diagnosing a threatened miscarriage, comprising detecting the level of an endocannabinoid in a body fluid sample from a subject mammal.
GBGB0723882.7A 2007-12-07 2007-12-07 Methods for the detection of a threatened miscarriage Ceased GB0723882D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0723882.7A GB0723882D0 (en) 2007-12-07 2007-12-07 Methods for the detection of a threatened miscarriage
PCT/GB2008/051162 WO2009071950A1 (en) 2007-12-07 2008-12-05 Methods for the detection of a threatened miscarriage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0723882.7A GB0723882D0 (en) 2007-12-07 2007-12-07 Methods for the detection of a threatened miscarriage

Publications (1)

Publication Number Publication Date
GB0723882D0 true GB0723882D0 (en) 2008-01-23

Family

ID=39016309

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0723882.7A Ceased GB0723882D0 (en) 2007-12-07 2007-12-07 Methods for the detection of a threatened miscarriage

Country Status (2)

Country Link
GB (1) GB0723882D0 (en)
WO (1) WO2009071950A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0921156D0 (en) * 2009-12-02 2010-01-20 Ucl Business Plc Biomarkers of early miscarriage
CN108020625A (en) * 2017-12-01 2018-05-11 上海宝藤生物医药科技股份有限公司 Method for detecting contents of arachidonic acid ethanolamine and 2-arachidonic acid glycerol in blood plasma and threatened abortion diagnostic kit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
EA009279B1 (en) * 2001-09-12 2007-12-28 Апплайд Резеч Системз Арс Холдинг Н.В. Use of human chorionic gonadotropin for use in conjunction with follicle stimulating hormone for aiding implantation and/or decreasing miscarriage rates
GB0405133D0 (en) * 2004-03-08 2004-04-07 Univ Leicester Detection of preterm labour
WO2006044617A1 (en) * 2004-10-15 2006-04-27 The Scripps Research Institute Oxadiazole ketone inhibitors of fatty acid amide hydrolase
US7955816B2 (en) * 2006-05-02 2011-06-07 Universita Degli Studi Di Roma “Tor Vergata” Design and synthesis of biotinylated probes for N-acyl-ethanolamines

Also Published As

Publication number Publication date
WO2009071950A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
EP2804001A3 (en) Methods for diagnosing prostate carcinomas
TR201903235T4 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF KIDNEY DAMAGE AND KIDNEY FAILURE.
WO2008135862A3 (en) Devices and methods for detecting analytes
WO2010025393A3 (en) Protein biomarkers and methods for diagnosing kawasaki disease
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2011010826A (en) Diagnostic devices and related methods.
WO2010019553A3 (en) Biomarker detection process and assay of neurological condition
MX2013001042A (en) Pancreatic cancer biomarkers and uses thereof.
EP2273168A3 (en) Valve failure detection
WO2010056337A3 (en) Methods and systems of using exosomes for determining phenotypes
MX351779B (en) PREDICTING GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NENs).
WO2010148391A3 (en) Biomarker assay of neurological condition
NZ624609A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP1989551A4 (en) Method of detecting or diagnosing of a neurodegenerative disease or condition
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2013188686A3 (en) Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome
WO2009111033A3 (en) Detection of biomarkers and biomarker complexes
NZ594772A (en) Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c
NZ624614A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011074802A3 (en) Kit for diagnosing prostate cancer and diagnosis method
EP2569635A4 (en) Methods for diagnosing and treating encephalitis or epilepsy
NZ628085A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ606124A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013112836A3 (en) Diagnostic and prognostic biomarkers for cancer
NZ601648A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)